ST
SRPT icon

Spot Trading’s Sarepta Therapeutics SRPT Stock Holding History

Spot Trading’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$2.22M Buy
48,931
+10,706
+28% +$428K 0.04% 672
2017
Q2 		$1.29M Buy
38,225
+27,309
+250% +$889K 0.03% 929
2017
Q1 		$323K Sell
10,916
-2,715
-20% -$84K 0.01% 1571
2016
Q4 		$374K Sell
13,631
-45,322
-77% -$1.82M 0.01% 1580
2016
Q3 		$3.62M Buy
58,953
+23,209
+65% +$702K 0.07% 382
2016
Q2 		$682K Buy
35,744
+33,326
+1,378% +$617K 0.01% 1395
2016
Q1 		$47K Sell
2,418
-12,511
-84% -$219K ﹤0.01% 2833
2015
Q4 		$576K Sell
14,929
-37,267
-71% -$1.21M 0.01% 1821
2015
Q3 		$1.68M Buy
52,196
+2,644
+5% +$89.7K 0.02% 1211
2015
Q2 		$1.51M Buy
49,552
+29,937
+153% +$612K 0.01% 1333
2015
Q1 		$260K Sell
19,615
-17,858
-48% -$238K ﹤0.01% 2576
2014
Q4 		$542K Sell
37,473
-28,927
-44% -$490K ﹤0.01% 2286
2014
Q3 		$1.4M Buy
66,400
+27,645
+71% +$624K 0.01% 1826
2014
Q2 		$1.16M Buy
38,755
+9,108
+31% +$288K 0.01% 2027
2014
Q1 		$712K Buy
+29,647
New +$756K ﹤0.01% 2265

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Spot Trading's SRPT Position: Q3 2017 in Review

Spot Trading increased its Sarepta Therapeutics (SRPT) stake by 28% in Q3 2017, buying an estimated $428K and bringing the position to 48,931 shares worth $2.22M. The position accounts for 0.04% of the portfolio, ranked #672.

Spot Trading first reported a position in SRPT in Q1 2014 and has held it in 15 quarters since. The position peaked at $3.62M in Q3 2016. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

  • Spot Trading held 48,931 shares of Sarepta Therapeutics worth $2.22M as of Q3 2017.
  • Spot Trading bought 10,706 Sarepta Therapeutics shares in Q3 2017, an estimated $428K.
  • Sarepta Therapeutics made up 0.04% of Spot Trading's portfolio in Q3 2017, its #672 holding.
  • Spot Trading first reported a position in Sarepta Therapeutics in Q1 2014 and has held it in 15 quarters since.
  • Spot Trading's Sarepta Therapeutics position peaked at $3.62M in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.